Pelthos Therapeutics (PTHS) Capital Expenditures (2026)
Pelthos Therapeutics (PTHS) posted Capital Expenditures of $196000.0 for Q2 2026, up 1.03% on a QoQ basis from $194000.0 in Q1 2026.
Powered by 
Analysis
Pelthos Therapeutics (PTHS) Capital Expenditures (2026) Analysis & Trends
Pelthos Therapeutics has reported Capital Expenditures for 1 years, with the latest figure at $196000.0 in Q2 2026.
- On a quarterly basis, Capital Expenditures changed N/A year-over-year to $196000.0 in Q2 2026; TTM through Jun 2026 was $390000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $99000.0, changed N/A from the prior year.
- Capital Expenditures was $196000.0 for Q2 2026 at Pelthos Therapeutics, up from $194000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $196000.0 in Q2 2026, with the low at $194000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.34 Bn | 621.58 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 446.74 Bn | 440.17 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 357.89 Bn | 350.75 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 267.44 Bn | 259.75 Bn | 11.24 Bn | -321.00 Mn |
| 5 | Pfizer | 156.55 Bn | 144.85 Bn | 10.94 Bn | 533.00 Mn |
| 6 | Sanofi | 52.21 Bn | 44.83 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.85 Bn | 42.85 Bn | - | 2.29 Mn |
| 8 | Incyte | 24.63 Bn | 20.09 Bn | 1.57 Bn | 12.41 Mn |
| 9 | United Therapeutics | 21.40 Bn | 18.74 Bn | 683.80 Mn | 108.00 Mn |
| 10 | Pelthos Therapeutics | 80.13 Mn | 55.57 Mn | 21.23 Mn | 196,000.00 |